Metabolism and Cancer

The Metabolism and Cancer group adopts the view that cancer diseases are governed by metabolic reprogramming. Our laboratory pursues to understand the contribution of dysregulated metabolism in cancer initiation, drug resistance, and metastatic progression using laboratory-based experimental and computational tools through completion of clinical proof-of-efficacy in cancer patients.

Main lines of research

Metabolism and cancer

Mechanistic understanding of metabolism-driven tumorigenesis
Metabolic mechanisms of cancer drug resistance
Identification of metabolic vulnerabilities as pharmacological targets for cancer therapy
Metabolomics and metabolic markers for early detection and clinical monitoring of cancer initiation, progression, and therapeutic resistance
Metabolo-epigenetics: Molecular aspects, computational modeling, and therapeutic development of precision medicine approaches

Mitochondrial dynamics and cancer

Role of autophagy and mitochondria fussion/fission in the generation of cancer stem cells
Mitochondrial dynamics-targeted therapeutics for cancer therapy

Natural biocompounds and cancer

Discovery and molecular characterization of natural biocompounds with anti-cancer properties
Pre-clinical development and clinical evaluation of natural biocompounds-based anti-cancer drugs

Metabolo-immunotherapy

Identification of metabolic nodes and small-molecule metabolites essential for the regulation of immune checkpoints in cancer cells
Metabolic and dietary interventions to boost the efficacy of immune checkpoint inhibitors (ICIs).
Computational development and pre-clinical validation of in silico clinical trials platforms for testing new metabolo-immunotherapy approaches

Computational systems biology in aging-driven cancer

Conceptual frameworks, stochastic tools, and wet-lab validation of metabolic and metabolo-epigenetic models of aging-driven cancer

Strategic objectives

To advance new metabolism-based anti-cancer therapeutics.

Publications

Metabolism and Cancer

Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin a 6 ß 1 drives endocrine resistance in breast cancer cells.

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882

Metabolism and Cancer , General and Digestive Surgery

Prognostic significance of the microbiome-adipose tissue axis in rectal cancer: protocol of a prospective observational study.

BJS Open, 2022, 6 dx.doi.org/10.1093/bjsopen/zrac009

Metabolism and Cancer

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8

Metabolism and Cancer

Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.

MOLECULAR ONCOLOGY, 2021, 15, 43-56 dx.doi.org/10.1002/1878-0261.12832

Metabolism and Cancer

Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, Erazo T, Diéguez-Martínez N, Espinosa-Gil S, Muñoz-Pinedo C, Yoldi G, Abad JL, Segura MF, Moran T, Romeo M, Bosch-Barrera J, Oaknin A, Alfón J, Domènech C, Fabriàs G, Velasco G, Lizcano JM

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

Autophagy, 2021, 17, 1-18 dx.doi.org/10.1080/15548627.2020.1761651

Metabolism and Cancer

Tramonti A, Cuyàs E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusà A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzolà F, Menendez JA

Metformin Is a Pyridoxal-5'-phosphate (PLP)-Competitive Inhibitor of SHMT2.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164009

Metabolism and Cancer , Descriptive epidemiology, genetics and cancer prevention

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168

Metabolism and Cancer

Verdura S, Cuyàs E, Ruiz-Torres V, Micol V, Joven J, Bosch-Barrera J, Menendez JA

Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Pharmaceuticals, 2021, 14 dx.doi.org/10.3390/ph14060559

Metabolism and Cancer

Menendez JA, Papadimitropoulou A, Vander Steen T, Cuyàs E, Oza-Gajera BP, Verdura S, Espinoza I, Vellon L, Mehmi I, Lupu R

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13051132

Metabolism and Cancer , Descriptive epidemiology, genetics and cancer prevention , Oncologia Radioteràpica i Física Mèdica de Girona

Niksic M, Redondo-Sanchez D, Chang YL, Rodriguez-Barranco M, Exposito-Hernandez J, Marcos-Gragera R, Oliva-Poch E, Bosch-Barrera J, Sanchez MJ, Luque-Fernandez MA

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.

Bmc Cancer, 2021, 21, 1048-1048 dx.doi.org/10.1186/s12885-021-08801-9

12 3 4 5 ›»

Competitive projects

Metabolism and Cancer

Dependencias metabólicas y regulación dietética de los puntos de control inmunitario: Nuevas dianas contra la resistencia a la inmunoterapia del cáncer

Codi oficial: PID2019-104055GB-I00 Start date:01/06/2020 Data fi: 31/05/2023 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO / Ajuda: 242,000 €

Metabolism and Cancer

Ayuda de personal Miquel Servet

Codi oficial: CP20/00003 Start date:01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €

Metabolism and Cancer

Estudi "Organ specific biomarkers and therapies to improve the management of brain metastasis".

Codi oficial: La Marató 201906-30 Start date:30/09/2020 Data fi: 29/09/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €

Transfer

Patents

Valiente Cortés Manuel, Priego Bendeck Neibla, Bosch Barrera Joaquim
MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS
Número de publicació: EP20170382891
Data de publicació: 2019-06-26

Job offers

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin a 6 ß 1 drives endocrine resistance in breast cancer cells.

Prognostic significance of the microbiome-adipose tissue axis in rectal cancer: protocol of a prospective observational study.

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

Metformin Is a Pyridoxal-5'-phosphate (PLP)-Competitive Inhibitor of SHMT2.

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.

Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.

Patents

Team

Group leader - R4

Established researchers - R3

Predoctorals researchers – R1

Collaborators

About IDIBGI!